ANEBULO PHARMACEUTICALS INC (ANEB)
OTCHealth CareBiotechnologySnapshot 2026-09-04
$0.36-8.05%
Close 2026-09-04 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANEB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 3.7 | 4.3 | 3.5 | 5.6 | 3.0 | 2.3 | — |
| Operating Income | (9.1) | (9.2) | (8.3) | (11.8) | (6.8) | (3.6) | — |
| Earnings from Continuing Operations | |||||||
| Interest Expense | 0.4 | 0.4 | 0.2 | — | — | 0.0 | — |
| Interest & Investment Income | — | — | — | — | — | 0.0 | — |
| Net Interest Expenses | — | — | — | — | — | 0.0 | — |
| Other Non-Operating Income / Expenses | 1.1 | 0.7 | 0.1 | 0.1 | 0.0 | (26.6) | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | (3.6) | — |
| Net Income | |||||||
| Net Income | (8.0) | (8.5) | (8.2) | (11.7) | (6.8) | (30.3) | — |
| Per Share | |||||||
| Basic EPS | (0.19) | (0.25) | (0.32) | (0.47) | 0.29 | (2.83) | — |
| Diluted EPS | (0.19) | (0.25) | (0.32) | (0.47) | 0.29 | — | — |
| Basic Weighted Avg Shares | 41.1 | 33.8 | 25.8 | 25.1 | 23.3 | 13.6 | — |
| Diluted Weighted Avg Shares | 41.1 | 33.8 | 25.8 | 25.1 | 23.3 | — | — |
| Supplemental | |||||||
| EBIT | (9.1) | (9.2) | (8.3) | (11.8) | (6.8) | (3.6) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.